Angiotensinogen and ACE gene polymorphisms and risk of atrial fibrillation in the general population

Pharmacogenetics and Genomics

Volumn 18, Issue 6, 2008, Pages 525-533

  Ravn, Lasse S ^a,e   Benn, Marianne ^b,c,e   Nordestgaard, Børge G ^c,d,e   Sethi, Amar A ^b,c,e   Agerholm Larsen, Birgit ^c,e   Jensen, Gorm B ^d,e   Tybjærg Hansen, Anne ^b,d,e  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Rigshospitalet   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d BISPEBJERG HOSPITAL   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Atrial fibrillation; Follow up study; Genetics; Renin angiotensin system; Risk factors

Indexed keywords

ADULT; AGED; ANGIOTENSIN CONVERTING ENZYME GENE; ANGIOTENSINOGEN GENE; ARTICLE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; FOLLOW UP; GENE; GENE DELETION; GENE FREQUENCY; GENE INSERTION; GENETIC VARIABILITY; GENOTYPE; HAZARD RATIO; HEART ATRIUM FIBRILLATION; HEART FAILURE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBESITY; POPULATION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK; SINUS RHYTHM;

ADULT; AGED; ALLELES; AMINO ACID SEQUENCE; ANGIOTENSINOGEN; ATRIAL FIBRILLATION; BASE SEQUENCE; DENMARK; DNA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; LINKAGE DISEQUILIBRIUM; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PEPTIDYL-DIPEPTIDASE A; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; SEQUENCE HOMOLOGY, AMINO ACID; SEQUENCE HOMOLOGY, NUCLEIC ACID;

EID: 44449119823     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3282fce3bd     Document Type: Article

References (25)

1. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114:e257-e354.
2. Goette A, Arndt M, Rocken C, Spiess A, Staack T, Geller JC, et al. Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation 2000; 101:2678-2681.
3. Li D, Shinagawa K, Pang L, Leung TK, Cardin S, Wang Z, Nattel S. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 2001; 104:2608-2614.
4. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999; 100:376-380.
5. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlof B, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the losartan intervention for end point reduction in hypertension (LIFE) study. J Am Coll Cardiol 2005; 45:712-719.
6. Ehrlich JR, Hohnloser SH, Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J 2006; 27:512-518.
7. Roberts R. Mechanisms of disease: genetic mechanisms of atrial fibrillation. Nat Clin Pract Cardiovasc Med 2006; 3:276-282.
8. Tsai CT, Lai LP, Lin JL, Chiang FT, Hwang JJ, Ritchie MD, et al. Renin-angiotensin system gene polymorphisms and atrial fibrillation. Circulation 2004; 109:1640-1646.
9. Schnohr P, Jensen G, Lange P. The Copenhagen city heart study-introduction. Eur Heart J 2001; 3 (suppl):H1-H83.
10. Friberg J, Scharling H, Gadsboll N, Jensen GB. Sex-specific increase in the prevalence of atrial fibrillation (The Copenhagen City Heart Study). Am J Cardiol 2003; 92:1419-1423.
11. Sethi AA, Nordestgaard BG, Gronholdt ML, Steffensen R, Jensen G, Tybjærg-Hansen A. Angiotensinogen single nucleotide polymorphisms, elevated blood pressure, and risk of cardiovascular disease. Hypertension 2003; 41:1202-1211.
12. Sethi AA, Nordestgaard BG, Agerholm-Larsen B, Frandsen E, Jensen G, Tybjærg-Hansen A. Angiotensinogen polymorphisms and elevated blood pressure in the general population: the Copenhagen City Heart Study. Hypertension 2001; 37:875-881.
13. Agerholm-Larsen B, Tybjærg-Hansen A, Frikke-Schmidt R, Gronholdt ML, Jensen G, Nordestgaard BG. ACE gene polymorphism as a risk factor for ischemic cerebrovascular disease. Ann Intern Med 1997; 127:346-355.
14. Mukamal KJ, Tolstrup JS, Friberg J, Jensen G, Gronbaek M. Alcohol consumption and risk of atrial fibrillation in men and women: the Copenhagen City Heart Study. Circulation 2005; 112:1736-1742.
15. Sethi AA, Nordestgaard BG, Tybjærg-Hansen A. Angiotensinogen gene polymorphism, plasma angiotensinogen, and risk of hypertension and ischemic heart disease: a meta-analysis. Arterioscler Thromb Vasc Biol 2003; 23:1269-1275.
16. Brand E, Chatelain N, Paillard F, Tiret L, Visvikis S, Lathrop M, et al. Detection of putative functional angiotensinogen (AGT) gene variants controlling plasma AGT levels by combined segregation-linkage analysis. Eur J Hum Genet 2002; 10:715-723.
17. Agerholm-Larsen B, Tybjærg-Hansen A, Schnohr P, Nordestgaard BG. ACE gene polymorphism explains 30-40% of variability in serum ACE activity in both women and men in the population at large: the Copenhagen City Heart Study. Atherosclerosis 1999; 147:425-427.
18. Staessen JA, Wang JG, Ginocchio G, Petrov V, Saavedra AP, Soubrier F, et al. The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular-renal risk. J Hypertens 1997; 15 (12 Pt 2):1579-1592.
19. Goette A, Staack T, Rocken C, Arndt M, Geller JC, Huth C, et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000; 35:1669-1677.
20. Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, Connolly SJ. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005; 45:1832-1839.
21. Webster MW, Fitzpatrick MA, Nicholls MG, Ikram H, Wells JE. Effect of enalapril on ventricular arrhythmias in congestive heart failure. Am J Cardiol 1985; 56:566-569.
22. Hanna N, Cardin S, Leung TK, Nattel S. Differences in atrial versus ventricular remodeling in dogs with ventricular tachypacing-induced congestive heart failure. Cardiovasc Res 2004; 63:236-244.
23. De Mello WC, Monterrubio J. Intracellular and extracellular angiotensin II enhance the L-type calcium current in the failing heart. Hypertension 2004; 44:360-364.
24. Ferron L, Capuano V, Ruchon Y, Deroubaix E, Coulombe A, Renaud JF. Angiotensin II signaling pathways mediate expression of cardiac T-type calcium channels. Circ Res 2003; 93:1241-1248.
25. Caballero R, Delpon E, Valenzuela C, Longobardo M, Tamargo J. Losartan and its metabolite E3174 modify cardiac delayed rectifier K( + ) currents. Circulation 2000; 101:1199-1205.